Effect of Anagliptin on Glycemic and Lipid Profile in Patients With Type 2 Diabetes Mellitus

BACKGROUND: Anagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor expected to improve the lipid profile as well as glycemic control. However, findings from large-scale prospective trials have not been obtained. METHODS: We performed a multicenter prospective trial in patients with type 2 diabetes...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Med Res
Hlavní autoři: Chiba, Yukari, Yamakawa, Tadashi, Tsuchiya, Hirohisa, Oba, Mari, Suzuki, Daisuke, Danno, Hirosuke, Takatsuka, Yoji, Shigematsu, Hiroshi, Kaneshiro, Mizuki, Terauchi, Yasuo
Médium: Artigo
Jazyk:Inglês
Vydáno: Elmer Press 2018
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6031245/
https://ncbi.nlm.nih.gov/pubmed/29977423
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14740/jocmr3464w
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky